Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Impact of Prior Lines of Therapy before Autologous Hematopoietic Cell Transplant on Survival in Standard Risk Multiple Myeloma

Hussein Awada, Ali Hajj Ali, Danai Dima, Craig S Sauter, Louis Williams, Jack Khouri, Shahzad Raza, Sandra Mazzoni, Jason Valent, Christy J. Samaras, Faiz Anwer

Blood (2023) 142 (Supplement 1): 7069.

https://doi.org/10.1182/blood-2023-189995

Published: 2023

Journal Articles

Molecular Expression Differences in Blood Mononuclear Cells in Patients with AL Amyloidosis

David Kaplan, Eric Christian, Jason Valent, Faiz Anwer, Shahzad Raza, Sandra Mazzoni, Christy J. Samaras, Louis S. Williams, Danai Dima, Kelly Shepherd, Jared Fennema, Sherry Fada, Megan Nakashima, Mazen Hanna, Hillard M. Lazarus, Jack Khouri

Blood (2023) 142 (Supplement 1): 5031.

https://doi.org/10.1182/blood-2023-180735

Published: 2023

Journal Articles

Outcomes of Venetoclax-Based Therapy in Patients with Daratumumab-Refractory t(11;14) Positive Light Chain Amyloidosis

Mark Orland, Danai Dima, Fauzia Ullah, Hussein Awada, Diana Basali, Beth M. Faiman, Cynthia Scott, Sandra Mazzoni, Louis S. Williams, Christy J. Samaras, Jason Valent, Faiz Anwer, Shahzad Raza, Jack Khouri

Blood (2023) 142 (Supplement 1): 2031.

https://doi.org/10.1182/blood-2023-183030

Published: 2023

Journal Articles

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

Blood (2023) 142 (Supplement 1): 7245.

https://doi.org/10.1182/blood-2023-190304

Published: 2023

Journal Articles

Insights into Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: A 12-Year Experience of a Large Academic Center

Danai Dima, Fauzia Ullah, Serhan Unlu, Diana Basali, Mahir Khan, Abdullah Saeed Khan, Xuefei Jia, Majid Jaberi-Douraki, Beth M. Faiman, Sandra Mazzoni, Louis S. Williams, Christy J. Samaras, Jason Valent, Faiz Anwer, Jack Khouri, Shahzad Raza

Blood (2023) 142 (Supplement 1): 3407.

https://doi.org/10.1182/blood-2023-181365

Published: 2023

Journal Articles

Outcomes of Salvage VDT-PACE-like Regimens in Relapsed-Refractory Multiple Myeloma: 10-Year Experience of a Large Academic Institution

Arooj Ahmed, Danai Dima, Kerri Row, Fauzia Ullah, Hussein Awada, Diana Basali, Heena Kurish, Mikhaila Rice, Joslyn Rudoni, Marissa Duco, Beth M. Faiman, Jack Khouri, Sandra Mazzoni, Louis S. Williams, Shahzad Raza, Christy J. Samaras, Jason Valent, Faiz Anwer

Blood (2023) 142 (Supplement 1): 4724.

https://doi.org/10.1182/blood-2023-182972

Published: 2023

Journal Articles

An Ensemble Machine Learning Model Using Gradient Boosting Identifies Patients with Disease Progression in Newly Diagnosed Multiple Myeloma

Louis S. Williams, Bardia Khosravi, Marko Velimirovic, Jack Khouri, Shahzad Raza, Sandra Mazzoni, Christy J. Samaras, Hussein Awada, Danai Dima, Jason Valent, Faiz Anwer

Blood (2023) 142 (Supplement 1): 1990.

https://doi.org/10.1182/blood-2023-188762

Published: 2023

Journal Articles

Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score

Rajshekhar Chakraborty, Lisa Rybicki, Wei Wei, Jason Valent, Beth M. Faiman, Christy J. Samaras, Faiz Anwer, Alok A. Khorana

Blood (2022) 140 (23): 2443–2450.

https://doi.org/10.1182/blood.2022015727

Published: 2022

Includes: Supplemental data

Journal Articles

Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma

Lauren M Granat, Hong Li, Faiz Anwer, Michael Sheu, Beth M. Faiman, Jack Khouri, Sandra Mazzoni, Jason Valent, Christy J. Samaras, Rajshekar Chakraborty, Chakra P Chaulagain, Willem J. van Heeckeren, Louis S. Williams

Blood (2022) 140 (Supplement 1): 4290–4291.

https://doi.org/10.1182/blood-2022-168040

Published: 2022

Journal Articles

Contemporary Use of VTD-PACE As Bridge Therapy in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma

Heena P Kurish, Kerri Row, Austin Kurkowski, Mikhaila Rice, Joslyn Rudoni, Jack Khouri, Sandra Mazzoni, Christy J. Samaras, Louis S. Williams, Willem van Heeckeren, Jason Valent, Faiz Anwer

Blood (2022) 140 (Supplement 1): 12496–12497.

https://doi.org/10.1182/blood-2022-162821

Published: 2022

Journal Articles

Long-Term Outcomes of Delayed Neutrophil Engraftment Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Hussein Awada, Adel Hajj Ali, Beth M. Faiman, Allison Winter, Sandra Mazzoni, Christy J. Samaras, Craig S. Sauter, Willem J. van Heeckeren, Robert M. Dean, Brad Pohlman, Brian T. Hill, Jason Valent, Ronald M. Sobecks, Louis S. Williams, Deepa Jagadeesh, Betty K. Hamilton, Matt Kalaycio, Jack Khouri, Faiz Anwer

Blood (2022) 140 (Supplement 1): 12924–12925.

https://doi.org/10.1182/blood-2022-170385

Published: 2022

Journal Articles

Long-Term Outcomes of Autologous Hematopoietic Cell Transplant of Multiple Myeloma: A 10 Year Follow up Study

Blood (2022) 140 (Supplement 1): 12920–12921.

https://doi.org/10.1182/blood-2022-168262

Published: 2022

Journal Articles

Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant

Blood (2022) 140 (Supplement 1): 10596–10597.

https://doi.org/10.1182/blood-2022-168810

Published: 2022

Journal Articles

External Validation of the Saved Score for Venous Thromboembolism Risk Stratification in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs

Danai Dima, Ang Li, Lauren M. Granat, Puneet Dhillon, Carmelo Gurnari, Anirudh Yalamanchali, Saeid Mirzai, Wei Wei, Beth M. Faiman, Louis S. Williams, Sandra Mazzoni, Christy J. Samaras, Faiz Anwer, Jason Valent, Jack Khouri

Blood (2022) 140 (Supplement 1): 11299–11300.

https://doi.org/10.1182/blood-2022-165722

Published: 2022

Journal Articles

The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10592–10593.

https://doi.org/10.1182/blood-2022-168433

Published: 2022

Journal Articles

Updated Organ Response Results of an Open-Label Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis Receiving Anti-Plasma Cell Therapy

Jason Valent, John Silowsky, Michael R. Kurman, Eileen Daniel, Janet Jobes, Mark Harnett, Sherry Fada, Michael Spector, Kathleen Stefunek, Heather Staley, Kristen Schlueter, Christy J. Samaras, Faiz Anwer, Jack Khouri, Jeffrey A. Zonder, Michaela Liedtke, Susan B. Sobolov

Blood (2021) 138 (Supplement 1): 2724.

https://doi.org/10.1182/blood-2021-148905

Published: 2021

Journal Articles

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

David S. Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD FRCPC, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V. Matous, MD, Kevin W Song, MD FRCPC, Christopher S. Seet, MD PhD, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand M. Anz, III, MD, Gustavo A. Fonseca, MD, Donna E. Reece, MD, Kim Lee, Weiyuan Chung, Amit Agarwal, MD PhD, Nizar J. Bahlis, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134189

Published: 2020

Journal Articles

Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-137235

Published: 2020

Journal Articles

Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score

Rajshekhar Chakraborty, MD, Lisa Rybicki, MS, Jason Valent, MD, Alex V. Mejia Garcia, MD, Beth M. Faiman, PhDCNP, Jack Khouri, MD, Nathaniel Rosko, PharmD, Christy J. Samaras, DO, Matt Kalaycio, MD, Faiz Anwer, MD, Alok A Khorana, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-137525

Published: 2020

Journal Articles

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Nathaniel Rosko, PharmD, Hanjie Mo, PharmD, Joslyn Rudoni, PharmD, Caitlin Siebenaller, PharmD, Sarah S Lee, MD, Rajshekar Chakraborty, MD, Beth M. Faiman, PhDCNP, Jack Khouri, MD, Alex V. Mejia Garcia, MD, Christy J. Samaras, DO, Faiz Anwer, MD, Jason Valent, MD

Blood (2019) 134 (Supplement_1): 1838.

https://doi.org/10.1182/blood-2019-124775

Published: 2019

NARROW

Impact of Prior Lines of Therapy before Autologous Hematopoietic Cell Transplant on Survival in Standard Risk Multiple Myeloma

Molecular Expression Differences in Blood Mononuclear Cells in Patients with AL Amyloidosis

Outcomes of Venetoclax-Based Therapy in Patients with Daratumumab-Refractory t(11;14) Positive Light Chain Amyloidosis

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

Insights into Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: A 12-Year Experience of a Large Academic Center

Outcomes of Salvage VDT-PACE-like Regimens in Relapsed-Refractory Multiple Myeloma: 10-Year Experience of a Large Academic Institution

An Ensemble Machine Learning Model Using Gradient Boosting Identifies Patients with Disease Progression in Newly Diagnosed Multiple Myeloma

Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score

Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma

Contemporary Use of VTD-PACE As Bridge Therapy in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma

Long-Term Outcomes of Delayed Neutrophil Engraftment Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Long-Term Outcomes of Autologous Hematopoietic Cell Transplant of Multiple Myeloma: A 10 Year Follow up Study

Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant

External Validation of the Saved Score for Venous Thromboembolism Risk Stratification in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs

The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Updated Organ Response Results of an Open-Label Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis Receiving Anti-Plasma Cell Therapy

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis

Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only